RICHMOND, Va.--(BUSINESS WIRE)--Commonwealth Biotechnologies, Inc. (CBI) (NASDAQ Capital Market: CBTE), announced today that it has been approved by the Department of Health and Human Services under the Select Agent Programs of the Centers for Disease Control and Prevention (CDC) and the Animal and Plant Health Inspection Service (APHIS) to carry out work on the highly pathogenic avian influenza (HPAI) – also called “ the bird flu virus”. The approval allows CBI to possess and use the virus within the United States.
